A Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that ...

After cutting coverage because of cost, the state health plan could return GLP-1 weight loss drugs to the plan ...

Omada Health is joining forces with CVS Health's Caremark as part of the pharmacy benefit manager's weight management program ...

The drug has been approved to help treat type-2 diabetes, but a new study shows an increase in use in people with type-1 diabetes, and it may not be safe.

The teenage years can be a minefield of insecurities—and for some, quick-fix beauty products offer tempting promises.

Research shows weight loss surgery can help reduce the risk of severe liver problems for some patients with MASH.

A groundbreaking study from the University of British Columbia has revealed a potentially disturbing side effect for those ...

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Losing weight is a common New Year’s resolution, and many people are now turning to advanced weight-loss medications like ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.